These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38443917)

  • 21. Probiotics
    Wang T; Zheng N; Luo Q; Jiang L; He B; Yuan X; Shen L
    Front Immunol; 2019; 10():1235. PubMed ID: 31214189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
    de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
    Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
    Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion.
    Fukuda Y; Kim SH; Bustos MA; Cho SN; Roszik J; Burks JK; Kim H; Hoon DSB; Grimm EA; Ekmekcioglu S
    Cancer Res Commun; 2023 Jul; 3(7):1397-1408. PubMed ID: 37529399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity.
    Zhang Z; Rafei-Shamsabadi D; Lehr S; Buettner N; Diehl R; Huzly D; Pinato DJ; Thimme R; Meiss F; Bengsch B
    J Transl Med; 2022 Dec; 20(1):582. PubMed ID: 36503532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.
    Lim SY; Shklovskaya E; Lee JH; Pedersen B; Stewart A; Ming Z; Irvine M; Shivalingam B; Saw RPM; Menzies AM; Carlino MS; Scolyer RA; Long GV; Rizos H
    Nat Commun; 2023 Mar; 14(1):1516. PubMed ID: 36934113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced Sarcomas.
    Rosenbaum E; Seier K; Bradic M; Kelly C; Movva S; Nacev BA; Gounder MM; Keohan ML; Avutu V; Chi P; Thornton KA; Chan JE; Dickson MA; Donoghue MTA; Tap WD; Qin LX; D'Angelo SP
    Cancer Res Commun; 2023 Oct; 3(10):2118-2125. PubMed ID: 37787759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8
    Watson RA; Tong O; Cooper R; Taylor CA; Sharma PK; de Los Aires AV; Mahé EA; Ruffieux H; Nassiri I; Middleton MR; Fairfax BP
    Sci Immunol; 2021 Oct; 6(64):eabj8825. PubMed ID: 34597125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.
    Shahabi V; Berman D; Chasalow SD; Wang L; Tsuchihashi Z; Hu B; Panting L; Jure-Kunkel M; Ji RR
    J Transl Med; 2013 Mar; 11():75. PubMed ID: 23521917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors.
    Reil KA; Tsuji S; Molina E; Nelson KL; McGuire KL; Giacalone MJ
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37290924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance.
    Cottrell T; Zhang J; Zhang B; Kaunitz GJ; Burman P; Chan HY; Verde F; Hooper JE; Hammers H; Allaf ME; Ji H; Taube J; Smith KN
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.
    Kfoury M; Najean M; Lappara A; Voisin AL; Champiat S; Michot JM; Laghouati S; Robert C; Besse B; Soria JC; Lambotte O; Massard C; Marabelle A; Texier M
    Cancer Treat Rev; 2022 Nov; 110():102452. PubMed ID: 35998515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.
    Lozano AX; Chaudhuri AA; Nene A; Bacchiocchi A; Earland N; Vesely MD; Usmani A; Turner BE; Steen CB; Luca BA; Badri T; Gulati GS; Vahid MR; Khameneh F; Harris PK; Chen DY; Dhodapkar K; Sznol M; Halaban R; Newman AM
    Nat Med; 2022 Feb; 28(2):353-362. PubMed ID: 35027754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4
    Kovacsovics-Bankowski M; Sweere JM; Healy CP; Sigal N; Cheng LC; Chronister WD; Evans SA; Marsiglio J; Gibson B; Swami U; Erickson-Wayman A; McPherson JP; Derose YS; Eliason AL; Medina CO; Srinivasan R; Spitzer MH; Nguyen N; Hyngstrom J; Hu-Lieskovan S
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms underlying immune-related adverse events during checkpoint immunotherapy.
    Zhou X; Chen X; Han L; Liu H
    Clin Sci (Lond); 2022 May; 136(10):771-785. PubMed ID: 35621125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
    Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
    Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.